Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02508532 · OUTCOME

Apparent Oral Clearance Unadjusted for Bioavailability (CL/F)

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors · Source last updated 2022-06-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
L/h
Interval / dispersion
Standard Deviation
Time frame
Cycle 1 Day 1

What was measured

Apparent oral clearance unadjusted for bioavailability (CL/F) following a single dose of avapritinib

Analysis population: Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD and available PK samples

Groups in this outcome

Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD

Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.

Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD

Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD23
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD8

Reported measurements

Source class 1
Values in L/h · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD31.515.2Not reportedNot reportedNot reported
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD29.920.1Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        15.2
        value
        31.5
      2. group Id
        OG001
        spread
        20.1
        value
        29.9
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    2. group Id
      OG001
      value
      8
    units
    Participants
description
Apparent oral clearance unadjusted for bioavailability (CL/F) following a single dose of avapritinib
dispersion Type
Standard Deviation
groups
  1. description
    Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.
    id
    OG000
    title
    Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD
  2. description
    Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.
    id
    OG001
    title
    Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
param Type
MEAN
population Description
Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD and available PK samples
reporting Status
POSTED
time Frame
Cycle 1 Day 1
title
Apparent Oral Clearance Unadjusted for Bioavailability (CL/F)
type
SECONDARY
unit Of Measure
L/h

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice